Trial Profile
A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Jun 2021
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Arbor Pharmaceuticals; XenoPort
- 07 Jun 2021 Status changed from active, no longer recruiting to recruiting.
- 19 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2016 Planned End Date changed from 1 Nov 2028 to 1 Jul 2024, as reported by ClinicalTrials.gov.